Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $.01 per share
-
Shares outstanding
-
7.01M
-
Number of holders
-
18
-
Total 13F shares, excl. options
-
1.73M
-
Shares change
-
+557K
-
Total reported value, excl. options
-
$3.98M
-
Value change
-
+$1.21M
-
Number of buys
-
10
-
Number of sells
-
-7
-
Price
-
$2.30
Significant Holders of Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) as of Q1 2025
21 filings reported holding TRAW - Traws Pharma, Inc. - Common Stock, par value $.01 per share as of Q1 2025.
Traws Pharma, Inc. - Common Stock, par value $.01 per share (TRAW) has 18 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.73M shares
of 7.01M outstanding shares and own 24.72% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (606K shares), PERCEPTIVE ADVISORS LLC (422K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (330K shares), Vestal Point Capital, LP (175K shares), Alyeska Investment Group, L.P. (52.6K shares), GEODE CAPITAL MANAGEMENT, LLC (33.4K shares), BOOTHBAY FUND MANAGEMENT, LLC (33.3K shares), Ikarian Capital, LLC (28.5K shares), UBS Group AG (14.3K shares), and VANGUARD GROUP INC (13.2K shares).
This table shows the top 18 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.